Document:

Exhibit 10.29

THIS SECURED DEBENTURE, AND THE SECURITIES INTO WHICH
IT IS CONVERTIBLE (COLLECTIVELY, THE "SECURITIES"), HAVE
NOT BEEN REGISTERED WITH THE UNITED STATES SECURITIES
AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION
OF ANY STATE.  THE SECURITIES ARE BEING OFFERED
PURSUANT TO A SAFE HARBOR FROM REGISTRATION UNDER
REGULATION D PROMULGATED UNDER THE SECURITIES ACT OF
1933, AS AMENDED (THE "ACT"). THE SECURITIES ARE
"RESTRICTED" AND MAY NOT BE OFFERED OR SOLD UNLESS THE
SECURITIES ARE REGISTERED UNDER THE ACT, PURSUANT TO
REGULATION D OR PURSUANT TO AVAILABLE EXEMPTIONS
FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND THE
COMPANY WILL BE PROVIDED WITH OPINION OF COUNSEL OR
OTHER SUCH INFORMATION AS IT MAY REASONABLY REQUIRE
TO CONFIRM THAT SUCH EXEMPTIONS ARE AVAILABLE.
FURTHER HEDGING TRANSACTIONS INVOLVING THE SECURITIES
MAY NOT BE MADE EXCEPT IN COMPLIANCE WITH THE ACT.

                          SECURED DEBENTURE
                     ACCESS PHARMACEUTICALS, INC.
                  7% Secured Convertible Debenture
                          March  30, 2006

              No.  HHF-001              US$1,316,500

This Secured Debenture (the "Debenture") is issued on March 30, 2005
(the "Closing Date") by Access Pharmaceuticals, Inc., a Delaware
corporation (the "Company"), to Highgate House Funds, Ltd. (together
with its permitted successors and assigns, the "Holder") pursuant to
exemptions from registration under the Securities Act of 1933, as
amended.

ARTICLE I.
Section 1.01     Principal and Interest.  For value received, the Company
hereby promises to pay to the order of the Holder on the one year
anniversary of the date hereof ("Maturity Date"), in lawful money of the
United States of America and in immediately available funds the principal
sum of One Million Three Hundred Sixteen Thousand Five Hundred
Dollars ($1,316,500), together with interest on the unpaid principal of this
Debenture at the rate of seven percent (7%) per year (compounded
monthly) from the date of this Debenture until paid in full.  The entire
principal amount and all accrued interest shall paid to the Holder on the
Maturity Date.  In no event shall the Holder be entitled to convert this
Debenture for a number of shares of Common Stock in excess of that
number of shares of Common Stock which, upon giving effect to such
conversion, would cause the aggregate number of shares of Common
Stock beneficially owned by the Holder and its affiliates to exceed 4.99%
of the outstanding shares of the Common Stock following such conversion
(unless the Holder provides the Company sixty five (65) days prior written
notice that this provision shall not apply).  For so long as the Common
Stock is listed on the American Stock Exchange or the Nasdaq, the total
number of shares issuable under this Debenture to the Holder, Cornell
Capital Partners, L.P. or their affiliates, and transferees, subsequent
transferees, or any other party pursuant to the Securities Purchase
Agreement of even date herewith among the Company, Cornell Capital
Partners, L.P., and Highgate House Funds, Ltd. (the "Securities Purchase
Agreement"), and the Pledge and Escrow Agreement of even date
herewith among the Company, Cornell Capital Partners, L.P., and
Highgate House Funds, Ltd. (the "Pledge Agreement") shall not exceed
Two Million Eight Hundred Ninety One Thousand Seven Hundred Twenty
Three (2,891,723) shares in the aggregate (representing approximately
19.9% of the  outstanding capital of the Company as of the date hereof),
absent the approval of the Company's shareholders.

Section 1.02     Monthly Repayment Schedule.  The Company shall make
six (6) scheduled payments ("Scheduled Payments") of principal, plus
accrued interest and a Redemption Premium ("Redemption Premium")
equal to 10% of the principal amount of each Scheduled Payment.  The
first Scheduled Payment shall be due and payable on November 1, 2005,
and shall continue on the first business day of each succeeding calendar
month thereafter.  The principal amount of each Scheduled Payment shall
be determined by dividing the outstanding principal amount of this
Debenture as of the date such Scheduled Payment is due by the number of
Scheduled Payments remaining.   For example, if on November 1, 2005,
the outstanding principal amount is $1,316,500, then the Scheduled
Payment due on November 1, 2005, would consist of $219,416.67 of
principal, plus a Redemption Premium of $21,942 and accrued interest on
$1,316,500 at a rate of 7% per year from the date hereof up to and
including October 31, 2005.

Section 1.03     Optional Conversion.  The Holder is entitled, at its option,
to convert, and sell on the same day, at any time and from time to time,
until payment in full of this Debenture, all or any part of the principal
amount of the Debenture, plus accrued interest, into shares (the
"Conversion Shares") of the Company's common stock, par value $0.01
per share ("Common Stock"), at the price per share (the "Conversion
Price") equal to $4.00 (the "Conversion Price").  No fraction of shares or
scrip representing fractions of shares will be issued on conversion, but the
number of shares issuable shall be rounded to the nearest whole share.  To
convert this Debenture, the Holder hereof shall deliver written notice
thereof, substantially in the form of Exhibit A to this Debenture, with
appropriate insertions (the "Conversion Notice"), to the Company at its
address as set forth herein.  The date upon which the conversion shall be
effective (the "Conversion Date") shall be deemed to be the date set forth
in the Conversion Notice.  The Holder has the right to convert this
Debenture after the Maturity Date.

Section 1.04     Reservation of Common Stock.  The Company shall reserve
and keep available out of its authorized but unissued shares of Common
Stock, solely for the purpose of effecting the conversion of this
Debenture, such number of shares of Common Stock as shall from time to
time be sufficient to effect such conversion, based upon the Conversion
Price.  If at any time the Company does not have a sufficient number of
Conversion Shares authorized and available, then the Company shall call
and hold a special meeting of its stockholders within thirty (30) days of
that time for the sole purpose of increasing the number of authorized
shares of Common Stock.

Section 1.05     Right of Redemption.  The Company at its option shall have
the right, with three (3) business days advance written notice, to redeem a
portion or all amounts outstanding under this Debenture prior to the
Maturity Date or any Scheduled Payment due date.  The Redemption
Premium shall apply to any such early redemptions.  The Company shall
pay a twenty percent (20%) premium (in lieu of the Redemption
Premium), on any Scheduled Payment not made within five (5) business
days of the date it is due.

Section 1.06     Registration Rights.  The Company is obligated to register
the resale of the Conversion Shares under the Securities Act of 1933, as
amended, pursuant to the terms of a Registration Rights Agreement,
among the Company, Cornell Capital Partners, LP and Highgate House
Funds, Ltd. of even date herewith (the "Investor Registration Rights
Agreement").

Section 1.07     Interest Payments.  The interest so payable shall be paid at
the time of a Scheduled Payment, maturity or conversion to the person in
whose name this Debenture is registered.  Interest shall be paid in
cash (via wire transfer or certified funds).  In the event of default, as
described in Article III Section 3.01 hereunder, the Holder may elect that
the interest be paid in cash (via wire transfer or certified funds) or in the
form of Common Stock.  If paid in the form of Common Stock, the
amount of stock to be issued will be calculated as follows: the value of the
stock shall be the Closing Bid Price on:  (i) the date the interest payment
is due; or (ii) if the interest payment is not made when due, the date the
interest payment is made.  A number of shares of Common Stock with a
value equal to the amount of interest due shall be issued.  No fractional
shares will be issued; therefore, in the event that the value of the Common
Stock per share does not equal the total interest due, the Company will
pay the balance in cash.

Section 1.08     Paying Agent and Registrar.  Initially, the Company will act
as paying agent and registrar.  The Company may change any paying
agent, registrar, or Company-registrar by giving the Holder not less than
ten (10) business days' written notice of its election to do so, specifying
the name, address, telephone number and facsimile number of the paying
agent or registrar.  The Company may act in any such capacity.

Section 1.09     Secured Nature of Debenture.  This Debenture is secured
by all of the assets and property of the Company as set forth on Exhibit A
to the Security Agreement dated the date hereof among the Company,
Cornell Capital Partners, LP, and Highgate House Funds, Ltd. (the
"Security Agreement") and the Pledged Shares as set forth in the Pledge
Agreement

ARTICLE II.
Section 2.01     Amendments and Waiver of Default.  The Debenture may
not be amended.  Notwithstanding the above, without the consent of the
Holder, the Debenture may be amended to cure any ambiguity, defect or
inconsistency, or to provide for assumption of the Company obligations to
the Holder.

ARTICLE III.
Section 3.01     Events of Default.  An Event of Default is defined as
follows: (a) failure by the Company to pay amounts due hereunder on the
Maturity Date; (b) failure by the Company to pay amounts due pursuant to
a Scheduled Payment within ten (10) days of the date such payment is due
(c) failure by the Company or the Company's transfer agent to deliver
Common Stock certificates to the Holder prior to the fifth (5th ) trading
day after a Conversion Date; (d) failure by the Company for ten (10) days
after notice to it to comply with any of its other agreements in the
Debenture; (d) events of bankruptcy or insolvency; (e) a breach by the
Company under the Investor Registration Rights Agreement, the Security
Agreement, the Pledge Agreement, or any of the  other Transaction
Documents (as defined in the Securities Purchase Agreement of even date
herewith among the Company, Cornell Capital Partners, LP, and Highgate
House Funds, Ltd. (the "Securities Purchase Agreement")) which is not
cured by the Company within any allocated cure period therein.  Upon the
occurrence of an Event of Default, the Holder may, in its sole discretion,
accelerate full repayment of all debentures outstanding and accrued interest
thereon or may, notwithstanding any limitations contained in this
Debenture and/or the Securities Purchase Agreement, convert all
debentures outstanding and accrued interest thereon into shares of
Common Stock pursuant to Section 1.03 herein.  Upon and Event of
Default, the Holder, in addition to any other remedies, shall have the right
(but not the obligation) to convert this Debenture at any time after an
Event of Default.

Section 3.02     Failure to Issue Unrestricted Common Stock. As indicated
in Article III Section 3.01, a breach by the Company of its obligations
under the Investor Registration Rights Agreement shall be deemed an
Event of Default, which if not cured within ten (10) days, shall entitle the
Holder to accelerate full repayment of all Debentures outstanding and
accrued interest thereon or, notwithstanding any limitations contained in
this Debenture and/or the Securities Purchase Agreement, to convert all
debentures outstanding and accrued interest thereon into shares of
Common Stock pursuant to Section 1.03 herein.  The Company
acknowledges that failure to honor a Notice of Conversion shall cause
irreparable harm to the Holder.

ARTICLE IV.
Section 4.01     Rights and Terms of Conversion.  This Debenture, in whole
or in part, may be converted at any time following the Closing Date, into
shares of Common Stock at a price equal to the Conversion Price as
described in Section 1.03 above.

Section 4.02     Re-issuance of Debenture.  When the Holder elects to
convert a part of the Debenture, then the Company shall reissue a new
Debenture in the same form as this Debenture to reflect the new principal
amount.

ARTICLE V.
Section 5.01     Anti-dilution.  If the Company, at any time while this
Debenture is outstanding, (a) shall pay a stock dividend or otherwise make
a distribution or distributions on shares of its Common Stock payable in
shares of its capital stock (whether payable in shares of its Common Stock
or of capital stock of any class), (b) subdivide outstanding shares of
Common Stock into a larger number of shares, (c) combine outstanding
shares of Common Stock into a smaller number of shares, or (d) issue by
reclassification any shares of capital stock of the Company, the
Conversion Price as applied in Section 1.03 shall be multiplied by a
fraction, the numerator of which shall be the number of shares of
Common Stock of the Company outstanding immediately before such
event and the denominator of which shall be the number of shares of
Common Stock outstanding immediately after giving effect to such event.
Any adjustment made pursuant to this Section 5.01 shall become effective
immediately after the record date for the determination of stockholders
entitled to receive such dividend or distribution and shall become effective
immediately after the effective date in the case of a subdivision,
combination or reclassification, provided that no adjustment shall be made
if the Company does not complete such dividend, distribution, subdivision,
combination or reclassification.

(1)      If the Company shall declare or make any dividend or other
distribution of its assets (or rights to acquire its assets) to holders of
Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities,
property or options by way of a dividend, spin off, reclassification,
corporate rearrangement or other similar transaction) (a "Distribution"), at
any time after the issuance of this Debenture, then, in each such case:

(i)      any Conversion Price in effect immediately prior to the close of
business on the record date fixed for the determination of holders of
Common Stock entitled to receive the Distribution shall be reduced,
effective as of the close of business on such record date, to a price
determined by multiplying such Conversion Price by a fraction of which
(A) the numerator shall be the closing bid price of the Common Stock on
the trading day immediately preceding such record date minus the value of
the Distribution (as determined in good faith by the Company's Board of
Directors) applicable to one share of Common Stock, and (B) the
denominator shall be the closing bid price of the Common Stock on the
trading day immediately preceding such record date; and

(ii)     either (A) the number of shares of Common Stock to be obtainable
upon exercise of this Debenture shall be increased to a number of shares
equal to the number of shares of Common Stock obtainable immediately
prior to the close of business on the record date fixed for the
determination of holders of Common Stock entitled to receive the
Distribution multiplied by the reciprocal of the fraction set forth in the
immediately preceding clause (i), or (B) in the event that the Distribution
is of common stock of a company whose common stock is traded on a
national securities exchange or a national automated quotation system, then
the holder of this Debenture shall receive an additional warrant, the terms
of which shall be identical to those of this Debenture, except that such
warrant shall be exercisable into the amount of the assets that would have
been payable to the holder of this Debenture pursuant to the Distribution
had the holder exercised this Debenture immediately prior to such record
date and with an exercise price equal to the amount by which the exercise
price of this Debenture was decreased with respect to the Distribution
pursuant to the terms of the immediately preceding clause (i). The newly
issued warrant shall have piggy-back right.

(2)      All calculations under this Section shall be made to the nearest
1/1000th of a cent or the nearest 1/1000th of a share, as the case may be.
Any calculation equal to or over .005 shall be rounded up to the next cent
or share and any calculation less than .005 shall be rounded down to the
previous cent or share.

(3)      Whenever the Conversion Price is adjusted pursuant to Section
5.01, the Company shall within one (1) Business Day after the
determination of the new Conversion Price mail and fax to the Holder, a
notice ("Company Notice of Conversion Price Adjustment") setting forth
the Conversion Price after such adjustment and setting forth a brief
statement of the factsrequiring such adjustment.

(4)      In case of any reclassification of the Common Stock, any
consolidation or merger of the Company with or into another person, the
sale or transfer of all or substantially all of the assets of the Company or
any compulsory share exchange pursuant to which the Common Stock is
converted into other securities, cash or property, then each holder of
Debentures then outstanding shall have the right thereafter to convert such
Debentures only into the shares of stock and other securities and property
receivable upon or deemed to be held by holders of Common Stock
following such reclassification, consolidation, merger, sale, transfer or
share exchange (except in the event the property is cash, then the Holder
shall have the right to convert the Debenture and receive cash in the same
manner as other stockholders), and the Holder shall be entitled upon such
event to receive such amount of securities or property as the holder of
shares of the Common Stock into which such Debenture could have been
converted immediately prior to such reclassification, consolidation,
merger, sale, transfer or share exchange would have been entitled.  The
terms of any such consolidation, merger, sale, transfer or share exchange
shall include such terms so as to continue to give to the Holder the right
to receive the securities or property set forth in this Section upon any
conversion following such consolidation, merger, sale, transfer or share
exchange.  This provision shall similarly apply to successive
reclassifications, consolidations, mergers, sales, transfers or share
exchanges;

(5)If:
(a) the Company shall declare a dividend (or any other distribution) on its
Common Stock; or

(b) the Company shall declare a special non-recurring cash dividend
redemption of its Common Stock; or

(c) the Company shall authorize the grant to all holders of the Common
Stock rights or warrants to subscribe for or purchase any shares of capital
stock of any class or of any rights; or

(d) the approval of any stockholders of the Company shall be required in
connection with any reclassification of the Common Stock of the Company
(other than a subdivision or combination of the outstanding shares of
Common Stock), any consolidation or merger to which the Company is a
party, any sale or transfer of all or substantially all of the assets of the
Company, or any compulsory share exchange whereby the Common Stock
is converted into other securities, cash or property; or

(e) the Company shall authorize the voluntary or involuntary dissolution,
liquidation or winding-up of the affairs of the Company;
then the Company shall cause to be filed at each office or agency
maintained for the purpose of conversion of Debentures, and shall cause to
be mailed and faxed to the Holder and each other holder of the Debentures
at their last addresses and facsimile number set forth in the Debenture
Register at least twenty (20) calendar days prior to the applicable record
or effective date hereinafter specified, a notice stating (x) the date on
which a record is to be taken for the purpose of such dividend,
distribution, redemption, rights or warrants, or if a record is not to be
taken, the date as of which the holders of Common Stock of record to be
entitled to such dividend, distributions, redemption, rights or warrants are
to be determined, or (y) the date on which such reclassification,
consolidation, merger, sale, transfer, share exchange, dissolution,
liquidation or winding-up is expected to become effective, and the date as
of which it is expected that holders of Common Stock of record shall be
entitled to exchange their shares of Common Stock for securities or other
property deliverable upon such reclassification, consolidation, merger,
sale, transfer, share exchange, dissolution, liquidation or winding-up;
provided, however, that the failure to mail such notice or any defect
therein or in the mailing thereof shall not affect the validity of the
corporate action required to be specified in such notice.

Section 5.02     If at any time conditions shall arise by reason of action or
failure to act by the Company, which action or failure to act, in the
opinion of the Board of Directors of the Company, is not adequately
covered by the other provisions hereof and which might materially and
adversely affect the rights of the Holder (different or distinguishable from
the effect generally on rights of holders of any class of the Company's
capital stock), the Company shall, at least twenty (20) calendar days prior
to the effective date of such action, mail and fax a written notice to each
holder of Debenture briefly describing the action contemplated, and an
appraiser selected by the holders of majority in principal amount of the
outstanding Debentures shall give its opinion as to the adjustment, if any
(not inconsistent with the standards established in this Section 5.01), of the
Conversion Price (including, if necessary, any adjustment as to the
securities into which Debentures may thereafter be convertible) and any
distribution which is or would be required to preserve without diluting the
rights of the holders of Debentures; provided, however, that the
Company, after receipt of the determination by such appraiser, shall have
the right to select an additional appraiser, in which case the adjustment
shall be equal to the average of the adjustments recommended by each
such appraiser.  The Company shall pay all fees and expenses of any
appraiser selected under this Section 5.02.  The Board of Directors of the
Company shall make the adjustment recommended forthwith upon the
receipt of such opinion or opinions or the taking of any such action
contemplated, as the case may be; provided, however, that no such
adjustment of the Conversion Price shall be made which, in the opinion of
the appraiser(s) giving the aforesaid opinion or opinions, would result in
an increase of the Conversion Price above the Conversion Price then in
effect.

Section 5.03     Consent  of Holder to Sell Capital Stock or Grant Security
Interests.  Except for shares of Common Stock issued to the Holder or its
affiliates under conversion of this Debenture or otherwise, so long as any
of the principal of or interest on this Debenture remains unpaid and
unconverted, the Company shall not, without the prior written consent of
the Holder, (a) issue or sell shares of Common Stock or Preferred Stock
without consideration or for a consideration per share less than the bid
price of the Common Stock determined immediately prior to its issuance,
(except upon exercise or conversion of any security that, pursuant to its
terms, is exercisable or convertible into the Company's Common Stock
and was issued or outstanding prior to the date hereof) (b) issue any
warrant, option, right, contract, call, or other security instrument granting
the holder thereof, the right to acquire Common Stock without
consideration or for a consideration less than such Common Stock's bid
price determined immediately prior to its issuance, (c) enter into any
security instrument granting the holder a security interest in any and all
assets of the Company that is senior to the security interest of the
Buyer(s), or (d) file any registration statement on Form S-8 except to
register up to 1,300,000 shares of the Common Stock to be issued under a
stock incentive plan.

Section 5.04     Not withstanding Section 5.03 above, the Company may,
without obtaining the prior written consent of the Buyer(s), issue or sell
shares of Common Stock or Preferred Stock for a consideration per share
of up to 20% below the closing bid price of the Common Stock
determined immediately prior to its issuance, provided that 50% of the net
proceeds of any such issuance are used to redeem the outstanding this
Debenture.

ARTICLE VI.
Section 6.01 Notice.  Notices regarding this Debenture shall be sent to the
parties at the following addresses, unless a party notifies the other parties,
in writing, of a change of address:

if to the Company, to:
Access Pharmaceuticals, Inc.
2600 Stemmons Freeway, Suite 176
Dallas, TX 75207
Attention:       Kerry P. Gray
Telephone:       (214) 905-5100
Facsimile:       (214) 905-5101

With a copy to:
Bingham McCutchen LLP
150 Federal Street
Boston, MA 02110-1726
Attention: John J. Concannon, Esq.
Telephone: (617) 951-8874
Facsimile: (617) 951-8736

If to the Holder:
Highgate House Funds, Ltd.
101 Hudson Street, Suite 3700
Jersey City, NJ  07303
Telephone: (201) 985-8300
Facsimile: (201) 985-8266

With a copy to: Troy Rillo, Esq.
101 Hudson Street, Suite 3700
Jersey City, NJ 07302
Telephone: (201) 985-8300
Facsimile: (201) 985-8266

Section 6.02 Governing Law.  This Debenture shall be deemed to be made
under and shall be construed in accordance with the laws of the State of
New Jersey without giving effect to the principals of conflict of laws
thereof.  Each of the parties consents to the jurisdiction of the
U.S. District Court sitting in the District of the State of New Jersey or the
state courts of the State of New Jersey sitting in Hudson County, New
Jersey in connection with any dispute arising under this Debenture and
hereby waives, to the maximum extent permitted by law, any objection,
including any objection based on forum non conveniens to the bringing of
any such proceeding in such jurisdictions.

Section 6.03 Severability.  The invalidity of any of the provisions of this
Debenture shall not invalidate or otherwise affect any of the other
provisions of this Debenture, which shall remain in full force and effect.

Section 6.04 Entire Agreement and Amendments.  This Debenture
represents the entire agreement between the parties hereto with respect to
the subject matter hereof and there are no representations, warranties or
commitments, except as set forth herein.  This Debenture may be
amended only by an instrument in writing executed by the parties hereto.

Section 6.05 Attorney Fees.        If the Company fails to strictly comply with
the terms of this Debenture, then the Company shall reimburse the Holder
promptly for all fees, costs and expenses, including, without limitation,
attorney's fees and expenses incurred by the Holder in any action in
connection with this Debenture, including, without limitation, those
incurred: (i) during any workout, attempted workout, and/or in connection
with the rendering of legal advice as to the Holder's rights, remedies and
obligations, (ii) collecting any sums which become due to the Holder, (iii)
defending or prosecuting any proceeding or any counterclaim to any
proceeding or appeal; or (iv) the protection, preservation or enforcement
of any rights or remedies of the Holder.

Section 6.06 Counterparts.  This Debenture may be executed in multiple
counterparts, each of which shall be an original, but all of which shall be
deemed to constitute on instrument.

IN WITNESS WHEREOF, with the intent to be legally bound hereby, the
Company as executed this Debenture as of the date first written above.

ACCESS PHARMACEUTICALS, INC.

By: /s/ Kerry P. Gray
   ------------------
Name: Kerry P. Gray
Title: President and Chief Executive Officer

<PAGE>
THIS SECURED DEBENTURE, AND THE SECURITIES INTO
WHICH IT IS CONVERTIBLE (COLLECTIVELY, THE
"SECURITIES"), HAVE NOT BEEN REGISTERED WITH THE
UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR
THE SECURITIES COMMISSION OF ANY STATE.  THE
SECURITIES ARE BEING OFFERED PURSUANT TO A SAFE
HARBOR FROM REGISTRATION UNDER REGULATION D
PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE "ACT").  THE SECURITIES ARE "RESTRICTED"
AND MAY NOT BE OFFERED OR SOLD UNLESS THE SECURITIES
ARE REGISTERED UNDER THE ACT, PURSUANT TO
REGULATION D OR PURSUANT TO AVAILABLE EXEMPTIONS
FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND
THE COMPANY WILL BE PROVIDED WITH OPINION OF
COUNSEL OR OTHER SUCH INFORMATION AS IT MAY
REASONABLY REQUIRE TO CONFIRM THAT SUCH EXEMPTIONS
ARE AVAILABLE.  FURTHER HEDGING TRANSACTIONS
INVOLVING THE SECURITIES MAY NOT BE MADE EXCEPT IN
COMPLIANCE WITH THE ACT.

                            SECURED DEBENTURE
                       ACCESS PHARMACEUTICALS, INC.
                      7% Secured Convertible Debenture
                             March  30, 2006

               No.  CCP-001              US$1,316,500

This Secured Debenture (the "Debenture") is issued on March 30, 2005
(the "Closing Date") by Access Pharmaceuticals, Inc., a Delaware
corporation (the "Company"), to Cornell Capital Partners, LP (together
with its permitted successors and assigns, the "Holder") pursuant to
exemptions from registration under the Securities Act of 1933, as
amended.

ARTICLE I.
Section 1.01     Principal and Interest.  For value received, the Company
hereby promises to pay to the order of the Holder on the one year
anniversary of the date hereof ("Maturity Date"), in lawful money of the
United States of America and in immediately available funds the principal
sum of One Million Three Hundred Sixteen Thousand Five Hundred
Dollars ($1,316,500), together with interest on the unpaid principal of this
Debenture at the rate of seven percent (7%) per year (compounded
monthly) from the date of this Debenture until paid in full.  The entire
principal amount and all accrued interest shall paid to the Holder on the
Maturity Date.  In no event shall the Holder be entitled to convert this
Debenture for a number of shares of Common Stock in excess of that
number of shares of Common Stock which, upon giving effect to such
conversion, would cause the aggregate number of shares of Common
Stock beneficially owned by the Holder and its affiliates to exceed 4.99%
of the outstanding shares of the Common Stock following such conversion
(unless the Holder provides the Company sixty five (65) days prior written
notice that this provision shall not apply).  For so long as the Common
Stock is listed on the American Stock Exchange or the Nasdaq, the total
number of shares issuable under this Debenture to the Holder, Highgate
House Funds, Ltd. or their affiliates, and transferees, subsequent
transferees, or any other party pursuant to the Securities Purchase
Agreement of even date herewith among the Company, Cornell Capital
Partners, L.P., and Highgate House Funds, Ltd. (the "Securities Purchase
Agreement"), and the Pledge and Escrow Agreement of even date
herewith among the Company, Cornell Capital Partners, L.P., and
Highgate House Funds, Ltd. (the "Pledge Agreement") shall not exceed
Two Million Eight Hundred Ninety One Thousand Seven Hundred Twenty
Three (2,891,723) shares in the aggregate (representing approximately
19.9% of the  outstanding capital of the Company as of the date hereof),
absent the approval of the Company's shareholders.

Section 1.02     Monthly Repayment Schedule.  The Company shall make
six (6) scheduled payments ("Scheduled Payments") of principal, plus
accrued interest and a Redemption Premium ("Redemption Premium")
equal to 10% of the principal amount of each Scheduled Payment.  The
first Scheduled Payment shall be due and payable on November 1, 2005,
and shall continue on the first business day of each succeeding calendar
month thereafter.  The principal amount of each Scheduled Payment shall
be determined by dividing the outstanding principal amount of this
Debenture as of the date such Scheduled Payment is due by the number of
Scheduled Payments remaining.   For example, if on November 1, 2005,
the outstanding principal amount is $1,316,500, then the Scheduled
Payment due on November 1, 2005, would consist of $219,416.67 of
principal, plus a Redemption Premium of $21,942 and accrued interest on
$1,316,500 at a rate of 7% per year from the date hereof up to and
including October 31, 2005.

Section 1.03     Optional Conversion.  The Holder is entitled, at its option,
to convert, and sell on the same day, at any time and from time to time,
until payment in full of this Debenture, all or any part of the principal
amount of the Debenture, plus accrued interest, into shares (the
"Conversion Shares") of the Company's common stock, par value $0.01
per share ("Common Stock"), at the price per share (the "Conversion
Price") equal to $4.00 (the "Conversion Price").  No fraction of shares or
scrip representing fractions of shares will be issued on conversion, but the
number of shares issuable shall be rounded to the nearest whole share.  To
convert this Debenture, the Holder hereof shall deliver written notice
thereof, substantially in the form of Exhibit A to this Debenture, with
appropriate insertions (the "Conversion Notice"), to the Company at its
address as set forth herein.  The date upon which the conversion shall be
effective (the "Conversion Date") shall be deemed to be the date set forth
in the Conversion Notice.  The Holder has the right to convert this
Debenture after the Maturity Date.

Section 1.04     Reservation of Common Stock.  The Company shall reserve
and keep available out of its authorized but unissued shares of Common
Stock, solely for the purpose of effecting the conversion of this
Debenture, such number of shares of Common Stock as shall from time to
time be sufficient to effect such conversion, based upon the Conversion
Price.  If at any time the Company does not have a sufficient number of
Conversion Shares authorized and available, then the Company shall call
and hold a special meeting of its stockholders within thirty (30) days of
that time for the sole purpose of increasing the number of authorized
shares of Common Stock.

Section 1.05     Right of Redemption.  The Company at its option shall have
the right, with three (3) business days advance written notice, to redeem a
portion or all amounts outstanding under this Debenture prior to the
Maturity Date or any Scheduled Payment due date.  The Redemption
Premium shall apply to any such early redemptions.  The Company shall
pay a twenty percent (20%) premium (in lieu of the Redemption
Premium), on any Scheduled Payment not made within five (5) business
days of the date it is due.

Section 1.06     Registration Rights.  The Company is obligated to register
the resale of the Conversion Shares under the Securities Act of 1933, as
amended, pursuant to the terms of a Registration Rights Agreement,
among the Company, Cornell Capital Partners, LP and Highgate House
Funds, Ltd. of even date herewith (the "Investor Registration Rights
Agreement").

Section 1.07     Interest Payments.  The interest so payable shall be paid at
the time of a Scheduled Payment, maturity or conversion to the person in
whose name this Debenture is registered.  Interest shall be paid in
cash (via wire transfer or certified funds).  In the event of default, as
described in Article III Section 3.01 hereunder, the Holder may elect that
the interest be paid in cash (via wire transfer or certified funds) or in the
form of Common Stock.  If paid in the form of Common Stock, the
amount of stock to be issued will be calculated as follows: the value of the
stock shall be the Closing Bid Price on:  (i) the date the interest payment
is due; or (ii) if the interest payment is not made when due, the date the
interest payment is made.  A number of shares of Common Stock with a
value equal to the amount of interest due shall be issued.  No fractional
shares will be issued; therefore, in the event that the value of the Common
Stock per share does not equal the total interest due, the Company will
pay the balance in cash.

Section 1.08     Paying Agent and Registrar.  Initially, the Company will act
as paying agent and registrar.  The Company may change any paying
agent, registrar, or Company-registrar by giving the Holder not less than
ten (10) business days' written notice of its election to do so, specifying
the name, address, telephone number and facsimile number of the paying
agent or registrar.  The Company may act in any such capacity.

Section 1.09     Secured Nature of Debenture.  This Debenture is secured
by all of the assets and property of the Company as set forth on Exhibit A
to the Security Agreement dated the date hereof among the Company,
Cornell Capital Partners, LP, and Highgate House Funds, Ltd. (the
"Security Agreement") and the Pledged Shares as set forth in the Pledge
Agreement

ARTICLE II.
Section 2.01     Amendments and Waiver of Default.  The Debenture may
not be amended.  Notwithstanding the above, without the consent of the
Holder, the Debenture may be amended to cure any ambiguity, defect or
inconsistency, or to provide for assumption of the Company obligations to
the Holder.

ARTICLE III.
Section 3.01     Events of Default.  An Event of Default is defined as
follows: (a) failure by the Company to pay amounts due hereunder on the
Maturity Date; (b) failure by the Company to pay amounts due pursuant to
a Scheduled Payment within ten (10) days of the date such payment is due
(c) failure by the Company or the Company's transfer agent to deliver
Common Stock certificates to the Holder prior to the fifth (5th ) trading
day after a Conversion Date; (d) failure by the Company for ten (10) days
after notice to it to comply with any of its other agreements in the
Debenture; (d) events of bankruptcy or insolvency; (e) a breach by the
Company under the Investor Registration Rights Agreement, the Security
Agreement, the Pledge Agreement, or any of the  other Transaction
Documents (as defined in the Securities Purchase Agreement of even date
herewith among the Company, Cornell Capital Partners, LP, and Highgate
House Funds, Ltd. (the "Securities Purchase Agreement")) which is not
cured by the Company within any allocated cure period therein.  Upon the
occurrence of an Event of Default, the Holder may, in its sole discretion,
accelerate full repayment of all debentures outstanding and accrued interest
thereon or may, notwithstanding any limitations contained in this
Debenture and/or the Securities Purchase Agreement, convert all
debentures outstanding and accrued interest thereon into shares of
Common Stock pursuant to Section 1.03 herein.  Upon and Event of
Default, the Holder, in addition to any other remedies, shall have the right
(but not the obligation) to convert this Debenture at any time after an
Event of Default.

Section 3.02     Failure to Issue Unrestricted Common Stock. As indicated
in Article III Section 3.01, a breach by the Company of its obligations
under the Investor Registration Rights Agreement shall be deemed an
Event of Default, which if not cured within ten (10) days, shall entitle the
Holder to accelerate full repayment of all Debentures outstanding and
accrued interest thereon or, notwithstanding any limitations contained in
this Debenture and/or the Securities Purchase Agreement, to convert all
debentures outstanding and accrued interest thereon into shares of
Common Stock pursuant to Section 1.03 herein.  The Company
acknowledges that failure to honor a Notice of Conversion shall cause
irreparable harm to the Holder.

ARTICLE IV.
Section 4.01     Rights and Terms of Conversion.  This Debenture, in whole
or in part, may be converted at any time following the Closing Date, into
shares of Common Stock at a price equal to the Conversion Price as
described in Section 1.03 above.

Section 4.02     Re-issuance of Debenture.  When the Holder elects to
convert a part of the Debenture, then the Company shall reissue a new
Debenture in the same form as this Debenture to reflect the new principal
amount.

ARTICLE V.
Section 5.01     Anti-dilution. If the Company, at any time while this
Debenture is outstanding, (a) shall pay a stock dividend or otherwise make
a distribution or distributions on shares of its Common Stock payable in
shares of its capital stock (whether payable in shares of its Common Stock
or of capital stock of any class), (b) subdivide outstanding shares of
Common Stock into a larger number of shares, (c) combine outstanding
shares of Common Stock into a smaller number of shares, or (d) issue by
reclassification any shares of capital stock of the Company, the
Conversion Price as applied in Section 1.03 shall be multiplied by a
fraction, the numerator of which shall be the number of shares of
Common Stock of the Company outstanding immediately before such
event and the denominator of which shall be the number of shares of
Common Stock outstanding immediately after giving effect to such event.
Any adjustment made pursuant to this Section 5.01 shall become effective
immediately after the record date for the determination of stockholders
entitled to receive such dividend or distribution and shall become effective
immediately after the effective date in the case of a subdivision,
combination or reclassification, provided that no adjustment shall be made
if the Company does not complete such dividend, distribution, subdivision,
combination or reclassification.

(1)      If the Company shall declare or make any dividend or other
distribution of its assets (or rights to acquire its assets) to holders of
Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities,
property or options by way of a dividend, spin off, reclassification,
corporate rearrangement or other similar transaction) (a "Distribution"), at
any time after the issuance of this Debenture, then, in each such case:

(i)      any Conversion Price in effect immediately prior to the close of
business on the record date fixed for the determination of holders of
Common Stock entitled to receive the Distribution shall be reduced,
effective as of the close of business on such record date, to a price
determined by multiplying such Conversion Price by a fraction of which
(A) the numerator shall be the closing bid price of the Common Stock on
the trading day immediately preceding such record date minus the value of
the Distribution (as determined in good faith by the Company's Board of
Directors) applicable to one share of Common Stock, and (B) the
denominator shall be the closing bid price of the Common Stock on the
trading day immediately preceding such record date; and

(ii)     either (A) the number of shares of Common Stock to be obtainable
upon exercise of this Debenture shall be increased to a number of shares
equal to the number of shares of Common Stock obtainable immediately
prior to the close of business on the record date fixed for the
determination of holders of Common Stock entitled to receive the
Distribution multiplied by the reciprocal of the fraction set forth in the
immediately preceding clause (i), or (B) in the event that the Distribution
is of common stock of a company whose common stock is traded on a
national securities exchange or a national automated quotation system, then
the holder of this Debenture shall receive an additional warrant, the terms
of which shall be identical to those of this Debenture, except that such
warrant shall be exercisable into the amount of the assets that would have
been payable to the holder of this Debenture pursuant to the Distribution
had the holder exercised this Debenture immediately prior to such record
date and with an exercise price equal to the amount by which the exercise
price of this Debenture was decreased with respect to the Distribution
pursuant to the terms of the immediately preceding clause (i). The newly
issued warrant shall have piggy-back right.

(2)      All calculations under this Section shall be made to the nearest
1/1000th of a cent or the nearest 1/1000th of a share, as the case may be.
Any calculation equal to or over .005 shall be rounded up to the next cent
or share and any calculation less than .005 shall be rounded down to the
previous cent or share.

(3)      Whenever the Conversion Price is adjusted pursuant to Section
5.01, the Company shall within one (1) Business Day after the
determination of the new Conversion Price mail and fax to the Holder, a
notice ("Company Notice of Conversion Price Adjustment") setting forth
the Conversion Price after such adjustment and setting forth a brief
statement of the factsrequiring such adjustment.

(4)      In case of any reclassification of the Common Stock, any
consolidation or merger of the Company with or into another person, the
sale or transfer of all or substantially all of the assets of the Company or
any compulsory share exchange pursuant to which the Common Stock is
converted into other securities, cash or property, then each holder of
Debentures then outstanding shall have the right thereafter to convert such
Debentures only into the shares of stock and other securities and property
receivable upon or deemed to be held by holders of Common Stock
following such reclassification, consolidation, merger, sale, transfer or
share exchange (except in the event the property is cash, then the Holder
shall have the right to convert the Debenture and receive cash in the same
manner as other stockholders), and the Holder shall be entitled upon such
event to receive such amount of securities or property as the holder of
shares of the Common Stock into which such Debenture could have been
converted immediately prior to such reclassification, consolidation,
merger, sale, transfer or share exchange would have been entitled.  The
terms of any such consolidation, merger, sale, transfer or share exchange
shall include such terms so as to continue to give to the Holder the right
to receive the securities or property set forth in this Section upon any
conversion following such consolidation, merger, sale, transfer or share
exchange.  This provision shall similarly apply to successive
reclassifications, consolidations, mergers, sales, transfers or share
exchanges;

(5)If:
(a)      the Company shall declare a dividend (or any other distribution) on
its Common Stock; or

(b)      the Company shall declare a special non-recurring cash dividend
redemption of its Common Stock; or

(c)      the Company shall authorize the grant to all holders of the
Common Stock rights or warrants to subscribe for or purchase any shares
of capital stock of any class or of any rights; or

(d)      the approval of any stockholders of the Company shall be required
in connection with any reclassification of the Common Stock of the
Company (other than a subdivision or combination of the outstanding
shares of Common Stock), any consolidation or merger to which the
Company is a party, any sale or transfer of all or substantially all of the
assets of the Company, or any compulsory share exchange whereby the
Common Stock is converted into other securities, cash or property; or

(e)      the Company shall authorize the voluntary or involuntary
dissolution, liquidation or winding-up of the affairs of the Company;

then the Company shall cause to be filed at each office or agency
maintained for the purpose of conversion of Debentures, and shall cause to
be mailed and faxed to the Holder and each other holder of the Debentures
at their last addresses and facsimile number set forth in the Debenture
Register at least twenty (20) calendar days prior to the applicable record
or effective date hereinafter specified, a notice stating (x) the date on
which a record is to be taken for the purpose of such dividend,
distribution, redemption, rights or warrants, or if a record is not to be
taken, the date as of which the holders of Common Stock of record to be
entitled to such dividend, distributions, redemption, rights or warrants are
to be determined, or (y) the date on which such reclassification,
consolidation, merger, sale, transfer, share exchange, dissolution,
liquidation or winding-up is expected to become effective, and the date as
of which it is expected that holders of Common Stock of record shall be
entitled to exchange their shares of Common Stock for securities or other
property deliverable upon such reclassification, consolidation, merger,
sale, transfer, share exchange, dissolution, liquidation or winding-up;
provided, however, that the failure to mail such notice or any defect
therein or in the mailing thereof shall not affect the validity of the
corporate action required to be specified in such notice.

Section 5.02     If at any time conditions shall arise by reason of action or
failure to act by the Company, which action or failure to act, in the
opinion of the Board of Directors of the Company, is not adequately
covered by the other provisions hereof and which might materially and
adversely affect the rights of the Holder (different or distinguishable from
the effect generally on rights of holders of any class of the Company's
capital stock), the Company shall, at least twenty (20) calendar days prior
to the effective date of such action, mail and fax a written notice to each
holder of Debenture briefly describing the action contemplated, and an
appraiser selected by the holders of majority in principal amount of the
outstanding Debentures shall give its opinion as to the adjustment, if any
(not inconsistent with the standards established in this Section 5.01), of the
Conversion Price (including, if necessary, any adjustment as to the
securities into which Debentures may thereafter be convertible) and any
distribution which is or would be required to preserve without diluting the
rights of the holders of Debentures; provided, however, that the
Company, after receipt of the determination by such appraiser, shall have
the right to select an additional appraiser, in which case the adjustment
shall be equal to the average of the adjustments recommended by each
such appraiser.  The Company shall pay all fees and expenses of any
appraiser selected under this Section 5.02.  The Board of Directors of the
Company shall make the adjustment recommended forthwith upon the
receipt of such opinion or opinions or the taking of any such action
contemplated, as the case may be; provided, however, that no such
adjustment of the Conversion Price shall be made which, in the opinion of
the appraiser(s) giving the aforesaid opinion or opinions, would result in
an increase of the Conversion Price above the Conversion Price then in
effect.

Section 5.03     Consent  of Holder to Sell Capital Stock or Grant Security
Interests.  Except for shares of Common Stock issued to the Holder or its
affiliates under conversion of this Debenture or otherwise, so long as any
of the principal of or interest on this Debenture remains unpaid and
unconverted, the Company shall not, without the prior written consent of
the Holder, (a) issue or sell shares of Common Stock or Preferred Stock
without consideration or for a consideration per share less than the bid
price of the Common Stock determined immediately prior to its issuance,
(except upon exercise or conversion of any security that, pursuant to its
terms, is exercisable or convertible into the Company's Common Stock
and was issued or outstanding prior to the date hereof) (b) issue any
warrant, option, right, contract, call, or other security instrument granting
the holder thereof, the right to acquire Common Stock without
consideration or for a consideration less than such Common Stock's bid
price determined immediately prior to its issuance, (c) enter into any
security instrument granting the holder a security interest in any and all
assets of the Company that is senior to the security interest of the
Buyer(s), or (d) file any registration statement on Form S-8 except to
register up to 1,300,000 shares of the Common Stock to be issued under a
stock incentive plan.

Section 5.04     Not withstanding Section 5.03 above, the Company may,
without obtaining the prior written consent of the Buyer(s), issue or sell
shares of Common Stock or Preferred Stock for a consideration per share
of up to 20% below the closing bid price of the Common Stock
determined immediately prior to its issuance, provided that 50% of the net
proceeds of any such issuance are used to redeem the outstanding this
Debenture.

ARTICLE VI.
Section 6.01     Notice.  Notices regarding this Debenture shall be sent to
the parties at the following addresses, unless a party notifies the other
parties, in writing, of a change of address:

If to the Company, to:
Access Pharmaceuticals, Inc.
2600 Stemmons Freeway, Suite 176
Dallas, TX 75207
Attention: Kerry P. Gray
Telephone: (214) 905-5100
Facsimile: (214) 905-5101

With a copy to:
Bingham McCutchen LLP
150 Federal Street
Boston, MA 02110-1726
Attention: John J. Concannon, Esq.
Telephone: (617) 951-8874
Facsimile: (617) 951-8736

If to the Holder:
Cornell Capital Partners, LP
101 Hudson Street, Suite 3700
Jersey City, NJ  07303
Telephone: (201) 985-8300
Facsimile: (201) 985-8266

With a copy to:
Troy Rillo, Esq.
101 Hudson Street, Suite 3700
Jersey City, NJ 07302
Telephone: (201) 985-8300
Facsimile: (201) 985-8266

Section 6.02     Governing Law.  This Debenture shall be deemed to be
made under and shall be construed in accordance with the laws of the
State of New Jersey without giving effect to the principals of conflict of
laws thereof.  Each of the parties consents to the jurisdiction of the
U.S. District Court sitting in the District of the State of New Jersey or the
state courts of the State of New Jersey sitting in Hudson County, New
Jersey in connection with any dispute arising under this Debenture and
hereby waives, to the maximum extent permitted by law, any objection,
including any objection based on forum non conveniens to the bringing of
any such proceeding in such jurisdictions.

Section 6.03     Severability.  The invalidity of any of the provisions of this
Debenture shall not invalidate or otherwise affect any of the other
provisions of this Debenture, which shall remain in full force and effect.

Section 6.04     Entire Agreement and Amendments.  This Debenture
represents the entire agreement between the parties hereto with respect to
the subject matter hereof and there are no representations, warranties or
commitments, except as set forth herein.  This Debenture may be
amended only by an instrument in writing executed by the parties hereto.

Section 6.05     Attorney Fees. If the Company fails to strictly comply
with the terms of this Debenture, then the Company shall reimburse the
Holder promptly for all fees, costs and expenses, including, without
limitation, attorney's fees and expenses incurred by the Holder in any
action in connection with this Debenture, including, without limitation,
those incurred: (i) during any workout, attempted workout, and/or in
connection with the rendering of legal advice as to the Holder's rights,
remedies and obligations, (ii) collecting any sums which become due to
the Holder, (iii) defending or prosecuting any proceeding or any
counterclaim to any proceeding or appeal; or (iv) the protection,
preservation or enforcement of any rights or remedies of the Holder.

Section 6.06     Counterparts.  This Debenture may be executed in multiple
counterparts, each of which shall be an original, but all of which shall be
deemed to constitute on instrument.

WITNESS WHEREOF, with the intent to be legally bound hereby, the
Company as executed this Debenture as of the date first written above.

ACCESS PHARMACEUTICALS, INC.

By:/s/ Kerry P. Gray
   -----------------
Name: Kerry P. Gray
Title: President and Chief Executive OfficerExhibit 10.28
                SECURITIES PURCHASE AGREEMENT

THIS SECURITIES PURCHASE AGREEMENT (this "Agreement"), dated
as of March 30, 2005, by and among ACCESS PHARMACEUTICALS,
INC., a Delaware corporation (the "Company"), and the Buyers listed on
Schedule I attached hereto (individually, a "Buyer" or collectively "Buyers").

WITNESSETH:

WHEREAS, the Company and the Buyer(s) are executing and delivering this
Agreement in reliance upon an exemption from securities registration
pursuant to Section 4(2) and/or Rule 506 of Regulation D ("Regulation D")
as promulgated by the U.S. Securities and Exchange Commission (the
"SEC") under the Securities Act of 1933, as amended (the "Securities Act");

WHEREAS, the parties desire that, upon the terms and subject to the
conditions contained herein, the Company shall issue and sell to the Buyer(s),
as provided herein, and the Buyer(s) shall purchase up to Two Million Six
Hundred Thirty Three Thousand Dollars ($2,633,000) of secured convertible
debentures (the "Convertible Debentures"), which shall be convertible into
shares of the Company's common stock, par value $0.01 (the "Common
Stock") (as converted, the "Conversion Shares") which shall be funded on the
fifth (5th) business day following the date hereof (the "Closing"), for a total
purchase price of Two Million Six Hundred Thirty Three Thousand Dollars
($2,633,000), (the "Purchase Price") in the respective amounts set forth
opposite each Buyer(s) name on Schedule I (the "Subscription Amount"); and

WHEREAS, contemporaneously with the execution and delivery of this
Agreement, the parties hereto are executing and delivering a Registration
Rights Agreement substantially in the form attached hereto as Exhibit A (the
"Investor Registration Rights Agreement") pursuant to which the Company
has agreed to provide certain registration rights under the Securities Act and
the rules and regulations promulgated there under, and applicable state
securities laws; and

WHEREAS, the aggregate proceeds of the sale of the Convertible Debentures
contemplated hereby shall be held in escrow pursuant to the terms of an
escrow agreement substantially in the form of the Escrow Agreement
attached hereto as Exhibit B.

WHEREAS contemporaneously with the execution and delivery of this
Agreement, the parties hereto are executing and delivering a security
agreements substantially in the form attached hereto as Exhibit C (the
"Security Agreement") pursuant to which the Company has agreed to provide
the Buyer a security interest in Pledged Collateral (as this term is defined in
the Security Agreement and the Subsidiary Security Agreements), subject to
a security interest on certain specific equipment granted to Agilent Financial
Services, Inc., to secure the Company's obligations under this Agreement,
the Convertible Debenture, the Investor Registration Rights Agreement, the
Irrevocable Transfer Agent Instructions, the Security Agreement, the Pledge
and Escrow Agreement or any other obligations of the Company to the
Buyer;

WHEREAS, contemporaneously with the execution and delivery of this
Agreement, the parties hereto are executing and delivering a Pledge and
Escrow Agreement substantially in the form attached hereto as Exhibit D (the
"Pledge and Escrow Agreement") pursuant to which the Company has agreed
to provide the Buyer a security interest in the Pledged Shares (as this term
is defined in the Pledge and Escrow Agreement) to secure the Company's
obligations under this Agreement, the Convertible Debenture, the Investor
Registration Rights Agreement, the Irrevocable Transfer Agent Instructions,
the Security Agreement, the Pledge and Escrow Agreement or any other
obligations of the Company to the Buyer; and

WHEREAS, contemporaneously with the execution and delivery of this
Agreement, the parties hereto are executing and delivering Irrevocable
Transfer Agent Instructions substantially in the form attached hereto as
Exhibit E (the "Irrevocable Transfer Agent Instructions")

NOW, THEREFORE, in consideration of the mutual covenants and other
agreements contained in this Agreement the Company and the Buyer(s)
hereby agree as follows:

1. PURCHASE AND SALE OF CONVERTIBLE DEBENTURES.

(a) Purchase of Convertible Debentures.  Subject to the satisfaction (or
waiver) of the terms and conditions of this Agreement, each Buyer agrees,
severally and not jointly, to purchase at Closing (as defined herein below)
and the Company agrees to sell and issue to each Buyer, severally and not
jointly, at Closing, Convertible Debentures in amounts corresponding with
the Subscription Amount set forth opposite each Buyer's name on Schedule
I hereto.  Upon execution hereof by a Buyer, the Buyer shall wire transfer
the Subscription Amount set forth opposite his name on Schedule I in same-
day funds or a check payable to "David Gonzalez, Esq., as Escrow Agent for
Access Pharmaceuticals, Inc./Cornell Capital Partners, LP", which
Subscription Amount shall be held in escrow pursuant to the terms of the
Escrow Agreement (as hereinafter defined) and disbursed in accordance
therewith.  Notwithstanding the foregoing, a Buyer may withdraw his
Subscription Amount and terminate this Agreement as to such Buyer at any
time after the execution hereof and prior to Closing (as hereinafter defined).

(b) Closing Date.  The Closing of the purchase and sale of the Convertible
Debentures shall take place at 10:00 a.m. Eastern Standard Time on the fifth
(5th) business day following the date hereof, subject to notification of
satisfaction of the conditions to the First Closing set forth herein and in
Sections 6 and 7 below (or such later date as is mutually agreed to by the
Company and the Buyer(s)) (the "Closing Date").  The Closing shall occur
on the Closing Date at the offices of Yorkville Advisors, LLC, 3700 Hudson
Street, Suite 3700, Jersey City, New Jersey 07302 (or such other place as is
mutually agreed to by the Company and the Buyer(s)).

(c) Escrow Arrangements; Form of Payment.  Upon execution hereof by
Buyer(s) and pending the Closings, the aggregate proceeds of the sale of the
Convertible Debentures to Buyer(s) pursuant hereto shall be deposited in a
non-interest bearing escrow account with David Gonzalez, Esq., as escrow
agent (the "Escrow Agent"), pursuant to the terms of an escrow agreement
between the Company, the Buyer(s) and the Escrow Agent in the form
attached hereto as Exhibit B (the "Escrow Agreement"). Subject to the
satisfaction of the terms and conditions of this Agreement, on the Closing
Date, (i) the Escrow Agent shall deliver to the Company in accordance with
the terms of the Escrow Agreement such aggregate proceeds for the
Convertible Debentures to be issued and sold to such Buyer(s), minus the
unpaid structuring fees and expenses of Yorkville Advisors Management,
LLC of Ten Thousand Dollars ($10,000) which shall be paid directly from
the gross proceeds held in escrow of the Closing and (ii) the Company shall
deliver to each Buyer, Convertible Debentures which such Buyer(s) is
purchasing in amounts indicated opposite such Buyer's name on Schedule I,
duly executed on behalf of the Company.

2. BUYER'S REPRESENTATIONS AND WARRANTIES.

Each Buyer represents and warrants, severally and not jointly, that:

(a) Investment Purpose.  Each Buyer is acquiring the Convertible Debentures
and, upon conversion of Convertible Debentures, the Buyer will acquire the
Conversion Shares then issuable, for its own account for investment only and
not with a view towards, or for resale in connection with, the public sale or
distribution thereof, except pursuant to sales registered or exempted under the
Securities Act; provided, however, that by making the representations herein,
such Buyer reserves the right to dispose of the Conversion Shares at any time
in accordance with or pursuant to an effective registration statement covering
such Conversion Shares or an available exemption under the Securities Act.

(b) Accredited Investor Status.  Each Buyer is an "Accredited Investor" as
that term is defined in Rule 501(a)(3) of Regulation D.

(c) Reliance on Exemptions.  Each Buyer understands that the Convertible
Debentures are being offered and sold to it in reliance on specific exemptions
from the registration requirements of United States federal and state securities
laws and that the Company is relying in part upon the truth and accuracy of,
and such Buyer's compliance with, the representations, warranties,
agreements, acknowledgments and understandings of such Buyer set forth
herein in order to determine the availability of such exemptions and the
eligibility of such Buyer to acquire such securities.

(d) Information.  Each Buyer and its advisors (and his or, its counsel), if
any, have been furnished with all materials relating to the business, finances
and operations of the Company and information he deemed material to
making an informed investment decision regarding his purchase of the
Convertible Debentures and the Conversion Shares, which have been
requested by such Buyer.  Each Buyer and its advisors, if any, have been
afforded the opportunity to ask questions of the Company and its
management.  Neither such inquiries nor any other due diligence
investigations conducted by such Buyer or its advisors, if any, or its
representatives shall modify, amend or affect such Buyer's right to rely on
the Company's representations and warranties contained in Section 3 below.
Each Buyer understands that its investment in the Convertible Debentures and
the Conversion Shares involves a high degree of risk.  Each Buyer is in a
position regarding the Company, which, based upon employment, family
relationship or economic bargaining power, enabled and enables such Buyer
to obtain information from the Company in order to evaluate the merits and
risks of this investment.  Each Buyer has sought such accounting, legal and
tax advice, as it has considered necessary to make an informed investment
decision with respect to its acquisition of the Convertible Debentures and the
Conversion Shares.

(e) No Governmental Review.  Each Buyer understands that no United States
federal or state agency or any other government or governmental agency has
passed on or made any recommendation or endorsement of the Convertible
Debentures or the Conversion Shares, or the fairness or suitability of the
investment in the Convertible Debentures or the Conversion Shares, nor have
such authorities passed upon or endorsed the merits of the offering of the
Convertible Debentures or the Conversion Shares.

(f) Transfer or Resale.  Each Buyer understands that except as provided in
the Investor Registration Rights Agreement: (i) the Convertible Debentures
have not been and are not being registered under the Securities Act or any
state securities laws, and may not be offered for sale, sold, assigned or
transferred unless (A) subsequently registered thereunder, or (B) such Buyer
shall have delivered to the Company an opinion of counsel, in a generally
acceptable form, to the effect that such securities to be sold, assigned or
transferred may be sold, assigned or transferred pursuant to an exemption
from such registration requirements; (ii) any sale of such securities made in
reliance on Rule 144 under the Securities Act (or a successor rule
thereto) ("Rule 144") may be made only in accordance with the terms of
Rule 144 and further, if Rule 144 is not applicable, any resale of such
securities under circumstances in which the seller (or the person through
whom the sale is made) may be deemed to be an underwriter (as that term
is defined in the Securities Act) may require compliance with some other
exemption under the Securities Act or the rules and regulations of the SEC
thereunder; and (iii) neither the Company nor any other person is under any
obligation to register such securities under the Securities Act or any state
securities laws or to comply with the terms and conditions of any exemption
thereunder.  The Company reserves the right to place stop transfer
instructions against the shares and certificates for the Conversion Shares.

(g) Legends.  Each Buyer understands that the certificates or other
instruments representing the Convertible Debentures and or the Conversion
Shares shall bear a restrictive legend in substantially the following form (and
a stop transfer order may be placed against transfer of such stock
certificates):

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE
SECURITIES LAWS.  THE SECURITIES HAVE BEEN ACQUIRED SOLELY FOR INVESTMENT
PURPOSES AND NOT WITH A VIEW TOWARD RESALE AND MAY NOT BE OFFERED FOR
SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF
1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS, OR AN
OPINION OF COUNSEL, IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION
IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE SECURITIES LAWS.

The legend set forth above shall be removed and the Company within two (2)
business days shall issue a certificate without such legend to the holder of the
Conversion Shares upon which it is stamped, if, unless otherwise required by
state securities laws, (i) in connection with a sale transaction, provided the
Conversion Shares are registered under the Securities Act or (ii) in
connection with a sale transaction, after such holder provides the Company
with an opinion of counsel, which opinion shall be in form, substance and
scope customary for opinions of counsel in comparable transactions, to the
effect that a public sale, assignment or transfer of the Conversion Shares may
be made without registration under the Securities Act.

(h) Authorization, Enforcement.  This Agreement has been duly and validly
authorized, executed and delivered on behalf of such Buyer and is a valid and
binding agreement of such Buyer enforceable in accordance with its terms,
except as such enforceability may be limited by general principles of equity
or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation
and other similar laws relating to, or affecting generally, the enforcement of
applicable creditors' rights and remedies.

(i) Receipt of Documents.  Each Buyer and his or its counsel has received
and read in their entirety:  (i) this Agreement and each representation,
warranty and covenant set forth herein, the Security Agreement, the Investor
Registration Rights Agreement, the Escrow Agreement, the Irrevocable
Transfer Agent Agreement, and the Pledge and Escrow Agreement; (ii) all
due diligence and other information necessary to verify the accuracy and
completeness of such representations, warranties and covenants; (iii) the
Company's Form 10-K for the fiscal year ended December 31, 2003; (iv) the
Company's Form 10-Q for the fiscal quarter ended September 30, 2004 and
(v) answers to all questions each Buyer submitted to the Company regarding
an investment in the Company; and each Buyer has relied on the information
contained therein and has not been furnished any other documents, literature,
memorandum or prospectus.

(j) Due Formation of Corporate and Other Buyers.  If the Buyer(s) is a
corporation, trust, partnership or other entity that is not an individual
person, it has been formed and validly exists and has not been organized
for the specific purpose of purchasing the Convertible Debentures and is not
prohibited from doing so.

(k) No Legal Advice From the Company.  Each Buyer acknowledges, that
it had the opportunity to review this Agreement and the transactions
contemplated by this Agreement with his or its own legal counsel and
investment and tax advisors.  Each Buyer is relying solely on such counsel
and advisors and not on any statements or representations of the Company
or any of its representatives or agents for legal, tax or investment advice with
respect to this investment, the transactions contemplated by this Agreement
or the securities laws of any jurisdiction.

3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

The Company represents and warrants to each of the Buyers that, except as
set forth in the SEC Documents (as defined herein):

(a) Organization and Qualification.  The Company and its subsidiaries are
corporations duly organized and validly existing in good standing under the
laws of the jurisdiction in which they are incorporated, and have the requisite
corporate power to own their properties and to carry on their business as now
being conducted.  Each of the Company and its subsidiaries is duly qualified
as a foreign corporation to do business and is in good standing in every
jurisdiction in which the nature of the business conducted by it makes such
qualification necessary, except to the extent that the failure to be so
qualified or be in good standing would not have a material adverse effect
on the Company and its subsidiaries taken as a whole.

(b) Authorization, Enforcement, Compliance with Other Instruments.  (i) The
Company has the requisite corporate power and authority to enter into and
perform this Agreement, the Security Agreement, the Investor Registration
Rights Agreement, the Irrevocable Transfer Agent Agreement, the Escrow
Agreement, the Pledge and Escrow Agreement, and any related agreements
(collectively the "Transaction Documents") and to issue the Convertible
Debentures and the Conversion Shares in accordance with the terms hereof
and thereof, (ii) the execution and delivery of the Transaction Documents by
the Company and the consummation by it of the transactions contemplated
hereby and thereby, including, without limitation, the issuance of the
Convertible Debentures the Conversion Shares  and the reservation for
issuance and the issuance of the Conversion Shares issuable upon conversion
or exercise thereof, have been duly authorized by the Company's Board of
Directors and no further consent or authorization is required by the
Company, its Board of Directors or its stockholders, (iii) the Transaction
Documents have been duly executed and delivered by the Company, (iv) the
Transaction Documents constitute the valid and binding obligations of the
Company enforceable against the Company in accordance with their terms,
except as such enforceability may be limited by general principles of equity
or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation
or similar laws relating to, or affecting generally, the enforcement of
creditors' rights and remedies.  The authorized officer of the Company
executing the Transaction Documents knows of no reason why the Company
cannot file the registration statement as required under the Investor
Registration Rights Agreement or perform any of the Company's other
obligations under such documents.

(c) Capitalization.  As of the date hereof the authorized capital stock of the
Company consists of 50,000,000 shares of Common Stock, par value $0.01
per share and 2,000,000 shares of Preferred Stock of which 15,536,299
shares of Common Stock and zero shares of Preferred Stock are issued and
outstanding.  All of such outstanding shares have been validly issued and are
fully paid and nonassessable.  Except as disclosed in the SEC Documents (as
defined in Section 3(f)), no shares of Common Stock are subject to
preemptive rights or any other similar rights or any liens or encumbrances
suffered or permitted by the Company.  Except as disclosed in the SEC
Documents, as of the date of this Agreement, (i) there are no outstanding
options, warrants, scrip, rights to subscribe to, calls or commitments of any
character whatsoever relating to, or securities or rights convertible into, any
shares of capital stock of the Company or any of its subsidiaries, or
contracts, commitments, understandings or arrangements by which the
Company or any of its subsidiaries is or may become bound to issue
additional shares of capital stock of the Company or any of its subsidiaries
or options, warrants, scrip, rights to subscribe to, calls or commitments of
any character whatsoever relating to, or securities or rights convertible into,
any shares of capital stock of the Company or any of its subsidiaries, (ii)
there are no outstanding debt securities and (iii) there are no agreements or
arrangements under which the Company or any of its subsidiaries is obligated
to register the sale of any of their securities under the Securities Act (except
pursuant to the Registration Rights Agreement and other resale registration
statement requirements relating to currently outstanding or issuable securities
described in the SEC Documents) and (iv) there are no outstanding
registration statements (other than resale registration statements relating to
currently outstanding or issuable securities described in the SEC Documents)
and there are no outstanding comment letters from the SEC or any other
regulatory agency.  There are no securities or instruments containing anti-
dilution or similar provisions that will be triggered by the issuance of the
Convertible Debentures as described in this Agreement.  The Company has
furnished to the Buyer true and correct copies of the Company's Articles of
Incorporation, as amended and as in effect on the date hereof (the "Articles
of Incorporation"), and the Company's By-laws, as in effect on the date
hereof (the "By-laws"), and the terms of all securities convertible into or
exercisable for Common Stock and the material rights of the holders thereof
in respect thereto other than stock options issued to employees and
consultants or other securities described in the SEC Documents.

(d) Issuance of Securities.  The Convertible Debentures are duly authorized
and, upon issuance in accordance with the terms hereof, shall be duly issued,
fully paid and nonassessable, are free from all taxes, liens and charges with
respect to the issue thereof.  The Conversion Shares issuable upon conversion
of the Convertible Debentures have been duly authorized and reserved for
issuance.  Upon conversion or exercise in accordance with the Convertible
Debentures the Conversion Shares will be duly issued, fully paid and
nonassessable.

(e) No Conflicts.  Except as disclosed in the SEC Documents, the execution,
delivery and performance of the Transaction Documents by the Company and
the consummation by the Company of the transactions contemplated hereby
will not (i) result in a violation of the Certificate of Incorporation, any
certificate of designations of any outstanding series of preferred stock of the
Company or the By-laws or (ii) conflict with or constitute a default (or an
event which with notice or lapse of time or both would become a default)
under, or give to others any rights of termination, amendment, acceleration
or cancellation of, any agreement, indenture or instrument to which the
Company or any of its subsidiaries is a party, or result in a violation of any
law, rule, regulation, order, judgment or decree (including federal and state
securities laws and regulations and the rules and regulations of The American
Stock Exchange on which the Common Stock is traded) applicable to the
Company or any of its subsidiaries or by which any property or asset of the
Company or any of its subsidiaries is bound or affected.  Except as disclosed
in the SEC Documents, neither the Company nor its subsidiaries is in
violation of any term of or in default under its Articles of Incorporation or
By-laws or their organizational charter or by-laws, respectively, or any
material contract, agreement, mortgage, indebtedness, indenture, instrument,
judgment, decree or order or any statute, rule or regulation applicable to the
Company or its subsidiaries.  The business of the Company and its
subsidiaries is not being conducted, and shall not be conducted in violation
of any material law, ordinance, or regulation of any governmental entity.
Except as specifically contemplated by this Agreement and as required under
the Securities Act and any applicable state securities laws, the Company is
not required to obtain any consent, authorization or order of, or make any
filing or registration with, any court or governmental agency in order for it
to execute, deliver or perform any of its obligations under or contemplated
by this Agreement or the Registration Rights Agreement in accordance with
the terms hereof or thereof.  Except as disclosed in the SEC Documents, all
consents, authorizations, orders, filings and registrations which the Company
is required to obtain pursuant to the preceding sentence have been obtained
or effected on or prior to the date hereof.  The Company and its subsidiaries
are unaware of any facts or circumstance, which might give rise to any of the
foregoing.

(f) SEC Documents: Financial Statements.  Since January 1, 2002, the
Company has filed all reports, schedules, forms, statements and other
documents required to be filed by it with the SEC under of the Securities
Exchange Act of 1934, as amended (the "Exchange Act") (all of the
foregoing filed prior to the date hereof or amended after the date hereof and
all exhibits included therein and financial statements and schedules thereto
and documents incorporated by reference therein, being hereinafter referred
to as the "SEC Documents").  The Company has delivered to the Buyers or
their representatives, or made available through the SEC's website at
http://www.sec.gov., true and complete copies of the SEC Documents.  As
of their respective dates, the financial statements of the Company disclosed
in the SEC Documents (the "Financial Statements") complied as to form in
all material respects with applicable accounting requirements and the
published rules and regulations of the SEC with respect thereto.  Such
financial statements have been prepared in accordance with generally
accepted accounting principles, consistently applied, during the periods
involved (except (i) as may be otherwise indicated in such Financial
Statements or the notes thereto, or (ii) in the case of unaudited interim
statements, to the extent they may exclude footnotes or may be condensed or
summary statements) and, fairly present in all material respects the financial
position of the Company as of the dates thereof and the results of its
operations and cash flows for the periods then ended (subject, in the case of
unaudited statements, to normal year-end audit adjustments).  No other
document provided by or on behalf of the Company to the Buyer which is
not included in the SEC Documents, including, without limitation,
information referred to in this Agreement, contains any untrue statement of
a material fact or omits to state any material fact necessary in order to make
the statements therein, in the light of the circumstances under which they
were made, not misleading.

(g) 10(b)-5.  The SEC Documents do not include any untrue statements of
material fact, nor do they omit to state any material fact required to be stated
therein necessary to make the statements made, in light of the circumstances
under which they were made, not misleading.

(h) Absence of Litigation.  Except as disclosed in the SEC Documents, there
is no action, suit, proceeding, inquiry or investigation before or by any court,
public board, government agency, self-regulatory organization or body
pending against or affecting the Company, the Common Stock or any of the
Company's subsidiaries, wherein an unfavorable decision, ruling or finding
would (i) have a material adverse effect on the transactions contemplated
hereby (ii) adversely affect the validity or enforceability of, or the authority
or ability of the Company to perform its obligations under, this Agreement
or any of the documents contemplated herein, or (iii) except as expressly
disclosed in the SEC Documents, have a material adverse effect on the
business, operations, properties, financial condition or results of  operations
of the Company and its subsidiaries taken as a whole.

(i) Acknowledgment Regarding Buyer's Purchase of the Convertible
Debentures.  The Company acknowledges and agrees that the Buyer(s) is
acting solely in the capacity of an arm's length purchaser with respect to this
Agreement and the transactions contemplated hereby.  The Company further
acknowledges that the Buyer(s) is not acting as a financial advisor or
fiduciary of the Company (or in any similar capacity) with respect to this
Agreement and the transactions contemplated hereby and any advice given
by the Buyer(s) or any of their respective representatives or agents in
connection with this Agreement and the transactions contemplated hereby is
merely incidental to such Buyer's purchase of the Convertible Debentures or
the Conversion Shares.  The Company further represents to the Buyer that
the Company's decision to enter into this Agreement has been based solely
on the independent evaluation by the Company and its representatives.

(j) No General Solicitation.  Neither the Company, nor any of its affiliates,
nor any person acting on its or their behalf, has engaged in any form of
general solicitation or general advertising (within the meaning of Regulation
D under the Securities Act) in connection with the offer or sale of the
Convertible Debentures or the Conversion Shares.

(k) No Integrated Offering.  Neither the Company, nor any of its affiliates,
nor any person acting on its or their behalf has, directly or indirectly, made
any offers or sales of any security or solicited any offers to buy any security,
under circumstances that would require registration of the Convertible
Debentures or the Conversion Shares under the Securities Act or cause this
offering of the Convertible Debentures or the Conversion Shares to be
integrated with prior offerings by the Company for purposes of the Securities
Act.

(l) Employee Relations.  Neither the Company nor any of its subsidiaries is
involved in any labor dispute nor, to the knowledge of the Company or any
of its subsidiaries, is any such dispute threatened.  None of the Company's
or its subsidiaries' employees is a member of a union and the Company and
its subsidiaries believe that their relations with their employees are good.

(m) Intellectual Property Rights.  The Company and its subsidiaries own or
possess adequate rights or licenses to use all trademarks, trade names, service
marks, service mark registrations, service names, patents, patent rights,
copyrights, inventions, licenses, approvals, governmental authorizations,
trade secrets and rights necessary to conduct their respective businesses as
now conducted.  The Company and its subsidiaries do not have any
knowledge of any infringement by the Company or its subsidiaries of
trademark, trade name rights, patents, patent rights, copyrights, inventions,
licenses, service names, service marks, service mark registrations, trade
secret or other similar rights of others, and, to the knowledge of the
Company there is no claim, action or proceeding being made or brought
against, or to the Company's knowledge, being threatened against, the
Company or its subsidiaries regarding trademark, trade name, patents, patent
rights, invention, copyright, license, service names, service marks, service
mark registrations, trade secret or other infringement; and the Company and
its subsidiaries are unaware of any facts or circumstances which might give
rise to any of the foregoing.

(n) Environmental Laws.  The Company and its subsidiaries are (i) in
compliance with any and all applicable foreign, federal, state and local laws
and regulations relating to the protection of human health and safety, the
environment or hazardous or toxic substances or wastes, pollutants or
contaminants "Environmental Laws"), (ii) have received all permits,
licenses or other approvals required of them under applicable Environmental
Laws to conduct their respective businesses and (iii) are in compliance with
all terms and conditions of any such permit, license or approval.

(o) Title.  Any real property and facilities held under lease by the Company
and its subsidiaries are held by them under valid, subsisting and enforceable
leases with such exceptions as are not material and do not interfere with the
use made and proposed to be made of such property and buildings by the
Company and its subsidiaries.

(p) Insurance.  The Company and each of its subsidiaries are insured by
insurers of recognized financial responsibility against such losses and risks
and in such amounts as management of the Company believes to be prudent
and customary in the businesses in which the Company and its subsidiaries
are engaged.  Neither the Company nor any such subsidiary has been refused
any insurance coverage sought or applied for and neither the Company nor
any such subsidiary has any reason to believe that it will not be able to renew
its existing insurance coverage as and when such coverage expires or to
obtain similar coverage from similar insurers as may be necessary to continue
its business at a cost that would not materially and adversely affect the
condition, financial or otherwise, or the earnings, business or operations of
the Company and its subsidiaries, taken as a whole.

(q) Regulatory Permits.  The Company and its subsidiaries possess all
material certificates, authorizations and permits issued by the appropriate
federal, state or foreign regulatory authorities necessary to conduct their
respective businesses, and neither the Company nor any such subsidiary has
received any notice of proceedings relating to the revocation or modification
of any such certificate, authorization or permit.

(r) Internal Accounting Controls.  The Company and each of its subsidiaries
maintain a system of internal accounting controls sufficient to provide
reasonable assurance that (i) transactions are executed in accordance with
management's general or specific authorizations, (ii) transactions are
recorded as necessary to permit preparation of financial statements in
conformity with generally accepted accounting principles and to maintain
asset accountability, and (iii) the recorded amounts for assets is compared
with the existing assets at reasonable intervals and appropriate action is taken
with respect to any differences.

(s) No Material Adverse Breaches, etc.  Except as set forth in the SEC
Documents, neither the Company nor any of its subsidiaries is subject to any
charter, corporate or other legal restriction, or any judgment, decree, order,
rule or regulation which in the judgment of the Company's officers has or is
expected in the future to have a material adverse effect on the business,
properties, operations, financial condition, results of operations or prospects
of the Company or its subsidiaries.  Except as set forth in the SEC
Documents, neither the Company nor any of its subsidiaries is in breach of
any contract or agreement which breach, in the judgment of the Company's
officers, has or is expected to have a material adverse effect on the business,
properties, operations, financial condition, results of operations or prospects
of the Company or its subsidiaries.

(t) Tax Status.  Except as set forth in the SEC Documents, the Company and
each of its subsidiaries has made and filed all federal and state income and
all other tax returns, reports and declarations required by any jurisdiction to
which it is subject and (unless and only to the extent that the Company and
each of its subsidiaries has set aside on its books provisions reasonably
adequate for the payment of all unpaid and unreported taxes) has paid all
taxes and other governmental assessments and charges that are material in
amount, shown or determined to be due on such returns, reports and
declarations, except those being contested in good faith and has set aside on
its books provision reasonably adequate for the payment of all taxes for
periods subsequent to the periods to which such returns, reports or
declarations apply.  There are no unpaid taxes in any material amount
claimed to be due by the taxing authority of any jurisdiction, and the officers
of the Company know of no basis for any such claim.

(u) Certain Transactions.  Except as set forth in the SEC Documents, and
except for arm's length transactions pursuant to which the Company makes
payments in the ordinary course of business upon terms no less favorable
than the Company could obtain from third parties and other than the grant of
stock options disclosed in the SEC Documents, none of the officers,
directors, or employees of the Company is presently a party to any
transaction with the Company (other than for services as employees, officers
and directors), including any contract, agreement or other arrangement
providing for the furnishing of services to or by, providing for rental of real
or personal property to or from, or otherwise requiring payments to or from
any officer, director or such employee or, to the knowledge of the Company,
any corporation, partnership, trust or other entity in which any officer,
director, or any such employee has a substantial interest or is an officer,
director, trustee or partner.

(v) Fees and Rights of First Refusal.  The Company is not obligated to offer
the securities offered hereunder on a right of first refusal basis or otherwise
to any third parties including, but not limited to, current or former
shareholders of the Company, underwriters, brokers, agents or other third
parties.

4. COVENANTS.

(a) Best Efforts.  Each party shall use its best efforts timely to satisfy each
of the conditions to be satisfied by it as provided in Sections 6 and 7 of this
Agreement.

(b) Form D.  The Company agrees to file a Form D with respect to the
Conversion Shares as required under Regulation D and to provide a copy
thereof to each Buyer promptly after such filing.  The Company shall, on or
before the Closing Date, take such action as the Company shall reasonably
determine is necessary to qualify the Conversion Shares, or obtain an
exemption for the Conversion Shares for sale to the Buyers at the Closing
pursuant to this Agreement under applicable securities or "Blue Sky" laws
of the states of the United States, and shall provide evidence of any such
action so taken to the Buyers on or prior to the Closing Date.

(c) Reporting Status.  Until the earlier of (i) the date as of which the
Buyer(s) may sell all of the Conversion Shares without restriction pursuant
to Rule 144(k) promulgated under the Securities Act (or successor thereto),
or (ii) the date on which (A) the Buyer(s) shall have sold all the Conversion
Shares and (B) none of the Convertible Debentures are outstanding (the
"Registration Period"), the Company shall file in a timely manner all reports
required to be filed with the SEC pursuant to the Exchange Act and the
regulations of the SEC thereunder, and the Company shall not terminate its
status as an issuer required to file reports under the Exchange Act even if
the Exchange Act or the rules and regulations thereunder would otherwise
permit such termination.

(d) Use of Proceeds.  The Company will use the proceeds from the sale of
the Convertible Debentures for general corporate and working capital
purposes.

(e) Reservation of Shares.  The Company shall take all action reasonably
necessary to at all times have authorized, and reserved for the purpose of
issuance, such number of shares of Common Stock as shall be necessary to
effect the issuance of the Conversion Shares.  If at any time the Company
does not have available such shares of Common Stock as shall from time to
time be sufficient to effect the conversion of all of the Conversion Shares of
the Company shall call and hold a special meeting of the shareholders within
sixty (60) days of such occurrence, for the sole purpose of increasing the
number of shares authorized.  The Company's management shall recommend
to the shareholders to vote in favor of increasing the number of shares of
Common Stock authorized.  Management shall also vote all of its shares in
favor of increasing the number of authorized shares of Common Stock.

(f) Listings or Quotation.  The Company shall promptly secure the listing or
quotation of the Conversion Shares upon each national securities exchange,
automated quotation system or The National Association of Securities Dealers
Inc.'s Over-The-Counter Bulletin Board ("OTCBB"), the American Stock
Exchange, or other market, if any, upon which shares of Common Stock are
then listed or quoted (subject to official notice of issuance) and shall use its
best efforts to maintain, so long as any other shares of Common Stock shall
be so listed, such listing of all Conversion Shares from time to time issuable
under the terms of this Agreement.

(g) Fees and Expenses.  Each of the Company and the Buyer(s) shall pay all
costs and expenses incurred by such party in connection with the negotiation,
investigation, preparation, execution and delivery of the Transaction
Documents.  The Company shall pay Yorkville Advisors Management LLC
a fee equal to ten percent (10%) of the Purchase Price.

(h) The Company shall pay a structuring fee to Yorkville Advisors
Management, LLC of Ten Thousand Dollars ($10,000) which shall be paid
directly from the proceeds of the Closing.

The Company shall pay the Buyers a non-refundable due diligence fee of
Two Thousand Five Hundred Dollars ($2,500) which was paid on February
28, 2005.

Upon the execution of this Agreement, the Company shall issue to the
Buyer(s) Fifty Thousand (50,000) shares of the Company's Common
Stock (the "Buyer's Shares")  The Buyer's Shares shall have "piggy-back"
and demand registration rights.

(i) Corporate Existence.  So long as any of the Convertible Debentures
remain outstanding, the Company shall not directly or indirectly consummate
any merger, reorganization, restructuring, reverse stock split consolidation,
sale of all or substantially all of the Company's assets or any similar
transaction or related transactions (each such transaction, an "Organizational
Change") unless, prior to the consummation of an Organizational Change, the
Company obtains the written consent of each Buyer or makes provision for
the repayment of the Convertible Debentures, as part of such Organizational
Change.  In any such case, the Company will make appropriate provision
with respect to such holders' rights and interests to insure that the provisions
of this Section 4(h) will thereafter be applicable to the Convertible
Debentures.

(j) Transactions With Affiliates.  So long as any Convertible Debentures are
outstanding, the Company shall not, and shall cause each of its subsidiaries
not to, enter into, amend, modify or supplement, or permit any subsidiary to
enter into, amend, modify or supplement any agreement, transaction,
commitment, or arrangement with any of its or any subsidiary's officers,
directors, person who were officers or directors at any time during the
previous two (2) years, stockholders who beneficially own five percent (5%)
or more of the Common Stock, or Affiliates (as defined below) or with any
individual related by blood, marriage, or adoption to any such individual or
with any entity in which any such entity or individual owns a five percent
(5%) or more beneficial interest (each a "Related Party"), except for (a)
customary employment arrangements and benefit programs on reasonable
terms, (b) any investment in an Affiliate of the Company,  (c) any
agreement, transaction, commitment, or arrangement on an arms-length basis
on terms no less favorable than terms which would have been obtainable
from a person other than such Related Party, (d) any agreement transaction,
commitment, or arrangement which is approved by a majority of the
disinterested directors of the Company, for purposes hereof, any director
who is also an officer of the Company or any subsidiary of the Company
shall not be a disinterested director with respect to any such agreement,
transaction, commitment, or arrangement.  "Affiliate" for purposes hereof
means, with respect to any person or entity, another person or entity that,
directly or indirectly, (i) has a ten percent (10%) or more equity interest in
that person or entity, (ii) has ten percent (10%) or more common ownership
with that person or entity, (iii) controls that person or entity, or (iv) shares
common control with that person or entity.  "Control" or "controls" for
purposes hereof means that a person or entity has the power, direct or
indirect, to conduct or govern the policies of another person or entity.

(k) Transfer Agent.  The Company covenants and agrees that, in the event
that the Company's agency relationship with the transfer agent should be
terminated for any reason prior to a date which is two (2) years after the
Closing Date, the Company shall immediately appoint a new transfer agent
and shall require that the new transfer agent execute and agree to be bound
by the terms of the Irrevocable Transfer Agent Instructions (as defined
herein).

(l) Restriction on Issuance of the Capital Stock. Except for shares of
Common Stock issued to the Buyers or their affiliates under conversion of
the Convertible Debentures or otherwise, so long as any Convertible
Debentures are outstanding, the Company shall not:

(i) without the prior written consent of the Buyer(s), (a) issue or sell shares
of Common Stock or Preferred Stock without consideration or for a
consideration per share less than the Bid Price of the Common Stock
determined immediately prior to its issuance, (b) issue any warrant, option,
right, contract, call, or other security instrument granting the holder thereof,
the right to acquire Common Stock without consideration or for a
consideration less than such Common Stock's Bid Price value determined
immediately prior to its issuance (except upon exercise or conversion of any
security that, pursuant to its terms, is exercisable or convertible into the
Company's Common Stock and was issued or outstanding prior to the date
hereof), (c) enter into any security instrument granting the holder a security
interest in any or all assets of the Company or its subsidiaries, or (d) file
any registration statement on Form S-8 except to register up to 1,300,000
shares of the Common Stock to be issued under a stock incentive plan, and

(ii) not withstanding Section 4(l)(i) above, the Company may, without
obtaining the prior written consent of the Buyer(s), issue or sell shares of
Common Stock or Preferred Stock for a consideration per share of up to 20%
below the closing Bid Price of the Common Stock determined immediately
prior to its issuance, provided that 50% of the net proceeds of any such
issuance are used to redeem the outstanding Convertible Debentures.

5. TRANSFER AGENT INSTRUCTIONS.

The Company shall issue the Irrevocable Transfer Agent Instructions to its
transfer agent irrevocably appointing David Gonzalez, Esq. as its agent for
purpose of having certificates issued, registered in the name of the Buyer(s)
or its respective nominee(s), for the Conversion Shares representing such
amounts of Convertible Debentures as specified from time to time by the
Buyer(s) to the Company upon conversion of the Convertible Debentures, for
interest owed pursuant to the Convertible Debenture, and for any and all
Liquidated Damages (as this term is defined in the Investor Registration
Rights Agreement).  David Gonzalez, Esq. shall be paid a cash fee of Fifty
Dollars ($50) for every occasion they act pursuant to the Irrevocable Transfer
Agent Instructions.  The Company shall not change its transfer agent without
the express written consent of the Buyer(s), which may be withheld by the
Buyer(s) in its sole discretion.  Prior to registration of the Conversion Shares
under the Securities Act, all such certificates shall bear the restrictive
legend specified in Section 2(g) of this Agreement.  The Company warrants
that no instruction other than the Irrevocable Transfer Agent Instructions
referred to in this Section 5, and stop transfer instructions to give effect
to Section 2(g) hereof (in the case of the Conversion Shares prior to
registration of such shares under the Securities Act) will be given by the
Company to its transfer agent with respect to the Conversion Shares and that
the Conversion Shares shall otherwise be freely transferable on the books
and records of the Company as and to the extent provided in this Agreement
and the Investor Registration Rights Agreement.  Nothing in this Section 5
shall affect in any way the Buyer's obligations and agreement to comply with
all applicable securities laws upon resale of Conversion Shares.  If the
Buyer(s) provides the Company with an opinion of counsel reasonable
satisfactory to the Company, in form, scope and substance customary for
opinions of counsel in comparable transactions to the effect that
registration of a resale by the Buyer(s) of any of the Conversion Shares
is not required under the Securities Act, the Company shall within
two (2) business days instruct its transfer
agent to issue one or more certificates in such name and in such
denominations as specified by the Buyer.  The Company acknowledges that
a breach by it of its obligations hereunder will cause irreparable harm to the
Buyer by vitiating the intent and purpose of the transaction contemplated
hereby.  Accordingly, the Company acknowledges that the remedy at law for
a breach of its obligations under this Section 5 will be inadequate and agrees,
in the event of a breach or threatened breach by the Company of the
provisions of this Section 5, that the Buyer(s) shall be entitled, in addition
to all other available remedies, to an injunction restraining any breach and
requiring immediate issuance and transfer, without the necessity of showing
economic loss and without any bond or other security being required.

6. CONDITIONS TO THE COMPANY'S OBLIGATION TO SELL.

The obligation of the Company hereunder to issue and sell the Convertible
Debentures to the Buyer(s) at the Closings is subject to the satisfaction, at or
before the Closing Date, of each of the following conditions, provided that
these conditions are for the Company's sole benefit and may be waived by
the Company at any time in its sole discretion:

(a) Each Buyer shall have executed the Transaction Documents and delivered
them to the Company.

(b) The Buyer(s) shall have delivered to the Escrow Agent the Purchase Price
for Convertible Debentures in respective amounts as set forth next to each
Buyer as outlined on Schedule I attached hereto and the Escrow Agent shall
have delivered the net proceeds to the Company by wire transfer of
immediately available U.S. funds pursuant to the wire instructions provided
by the Company.

(c) The representations and warranties of the Buyer(s) shall be true and
correct in all material respects as of the date when made and as of the
Closing Dates as though made at that time (except for representations and
warranties that speak as of a specific date), and the Buyer(s) shall have
performed, satisfied and complied in all material respects with the covenants,
agreements and conditions required by this Agreement to be performed,
satisfied or complied with by the Buyer(s) at or prior to the Closing Date.

7. CONDITIONS TO THE BUYER'S OBLIGATION TO PURCHASE.

The obligation of the Buyer(s) hereunder to Purchase the Convertible
Debentures at the Closing is subject to the satisfaction, at or before the
Closing Date, of each of the following conditions:

(i) The Company shall have executed the Transaction Documents and
delivered the same to the Buyer(s).

(ii) The Common Stock shall be authorized for listing on the American Stock
Exchange, trading in the Common Stock shall not have been suspended for
any reason, and all the Conversion Shares issuable upon the conversion of
the Convertible Debentures shall be approved for listing by the American
Stock Exchange.

(iii) The representations and warranties of the Company shall be true and
correct in all material respects (except to the extent that any of such
representations and warranties is already qualified as to materiality in Section
3 above, in which case, such representations and warranties shall be true and
correct without further qualification) as of the date when made and as of the
Closing Date as though made at that time (except for representations and
warranties that speak as of a specific date) and the Company shall have
performed, satisfied and complied in all material respects with the covenants,
agreements and conditions required by this Agreement to be performed,
satisfied or complied with by the Company at or prior to the Closing Date.
If requested by the Buyer, the Buyer shall have received a certificate,
executed by the President of the Company, dated as of the Closing Date, to
the foregoing effect and as to such other matters as may be reasonably
requested by the Buyer including, without limitation an update as of the
Closing Date regarding the representation contained in Section 3(c) above.

(iv) The Company shall have executed and delivered to the Buyer(s) the
Convertible Debentures in the respective amounts set forth opposite each
Buyer(s) name on Schedule I attached hereto.

(v) The Buyer(s) shall have received an opinion of counsel from Bingham
McCutchen LLP in a form satisfactory to the Buyer(s).

(vi) The Company shall have provided to the Buyer(s) a certificate of good
standing from the secretary of state from the state in which the company is
incorporated.

(vii) The Company shall have executed a form UCC-1 or such other forms
as may be required to perfect the Buyer's interest in the Pledged Property as
detailed in the Security Agreement and the Subsidiary Security Agreements
and provided proof of such filing to the Buyer(s).

(viii) The Company shall have delivered to the Escrow Agent the Pledged
Shares as well executed and medallion guaranteed stock bond powers as
required pursuant to the Pledge and Escrow Agreement.

(ix) The Company shall have provided to the Buyer an acknowledgement, to
the satisfaction of the Buyer, from the Company's certified public accountant
as to its ability to provide all consents required in order to file a
registration statement in connection with this transaction.

(x) The Company shall have reserved out of its authorized and unissued
Common Stock, solely for the purpose of effecting the conversion of the
Convertible Debentures, shares of Common Stock to effect the conversion of
all of the Conversion Shares then outstanding.

(xi) The Irrevocable Transfer Agent Instructions, in form and substance
satisfactory to the Buyer, shall have been delivered to and acknowledged in
writing by the Company's transfer agent.

8. INDEMNIFICATION.

(a) In consideration of the Buyer's execution and delivery of this Agreement
and acquiring the Convertible Debentures and the Conversion Shares
hereunder, and in addition to all of the Company's other obligations under
this Agreement, the Company shall defend, protect, indemnify and hold
harmless the Buyer(s) and each other holder of the Convertible Debentures
and the Conversion Shares, and all of their officers, directors, employees and
agents (including, without limitation, those retained in connection with the
transactions contemplated by this Agreement) (collectively, the "Buyer
Indemnitees") from and against any and all actions, causes of action, suits,
claims, losses, costs, penalties, fees, liabilities and damages, and expenses
in connection therewith (irrespective of whether any such Buyer Indemnitee
is a party to the action for which indemnification hereunder is sought), and
including reasonable attorneys' fees and disbursements (the "Indemnified
Liabilities"), incurred by the Buyer Indemnitees or any of them as a result
of, or arising out of, or relating to (a) any misrepresentation or breach of any
representation or warranty made by the Company in this Agreement, the
Convertible Debentures or the Investor Registration Rights Agreement or any
other certificate, instrument or document contemplated hereby or thereby, (b)
any breach of any covenant, agreement or obligation of the Company
contained in this Agreement, or the Investor Registration Rights Agreement
or any other certificate, instrument or document contemplated hereby or
thereby, or (c) any cause of action, suit or claim brought or made against
such Indemnitee and arising out of or resulting from the execution, delivery,
performance or enforcement of this Agreement or any other instrument,
document or agreement executed pursuant hereto by any of the Indemnities,
any transaction financed or to be financed in whole or in part, directly or
indirectly, with the proceeds of the issuance of the Convertible Debentures
or the status of the Buyer or holder of the Convertible Debentures  the
Conversion Shares,  as a Buyer of Convertible Debentures in the Company.
To the extent that the foregoing undertaking by the Company may be
unenforceable for any reason, the Company shall make the maximum
contribution to the payment and satisfaction of each of the Indemnified
Liabilities, which is permissible under applicable law.

(b) In consideration of the Company's execution and delivery of this
Agreement, and in addition to all of the Buyer's other obligations under this
Agreement, the Buyer shall defend, protect, indemnify and hold harmless the
Company and all of its officers, directors, employees and agents (including,
without limitation, those retained in connection with the transactions
contemplated by this Agreement) (collectively, the "Company Indemnitees")
from and against any and all Indemnified Liabilities incurred by the
Indemnitees or any of them as a result of, or arising out of, or relating to (a)
any misrepresentation or breach of any representation or warranty made by
the Buyer(s) in this Agreement, instrument or document contemplated hereby
or thereby executed by the Buyer, (b) any breach of any covenant, agreement
or obligation of the Buyer(s) contained in this Agreement,  the Investor
Registration Rights Agreement or any other certificate, instrument or
document contemplated hereby or thereby executed by the Buyer, or (c) any
cause of action, suit or claim brought or made against such Company
Indemnitee based on material misrepresentations or due to a material breach
and arising out of or resulting from the execution, delivery, performance or
enforcement of this Agreement, the Investor Registration Rights Agreement
or any other instrument, document or agreement executed pursuant hereto by
any of the Company Indemnities.  To the extent that the foregoing
undertaking by each Buyer may be unenforceable for any reason, each Buyer
shall make the maximum contribution to the payment and satisfaction of each
of the Indemnified Liabilities, which is permissible under applicable law.

9. GOVERNING LAW: MISCELLANEOUS.

(a) Governing Law.  This Agreement shall be governed by and interpreted
in accordance with the laws of the State of New Jersey without regard to the
principles of conflict of laws.  The parties further agree that any action
between them shall be heard in Hudson County, New Jersey, and expressly
consent to the jurisdiction and venue of the Superior Court of New Jersey,
sitting in Hudson County and the United States District Court for the District
of New Jersey sitting in Newark, New Jersey for the adjudication of any civil
action asserted pursuant to this Paragraph.

(b) Counterparts.  This Agreement may be executed in two or more identical
counterparts, all of which shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party
and delivered to the other party.  In the event any signature page is delivered
by facsimile transmission, the party using such means of delivery shall cause
four (4) additional original executed signature pages to be physically
delivered to the other party within five (5) days of the execution and delivery
hereof.

(c) Headings.  The headings of this Agreement are for convenience of
reference and shall not form part of, or affect the interpretation of, this
Agreement.

(d) Severability.  If any provision of this Agreement shall be invalid or
unenforceable in any jurisdiction, such invalidity or unenforceability shall not
affect the validity or enforceability of the remainder of this Agreement in that
jurisdiction or the validity or enforceability of any provision of this
Agreement in any other jurisdiction.

(e) Entire Agreement, Amendments.  This Agreement supersedes all other
prior oral or written agreements between the Buyer(s), the Company, their
affiliates and persons acting on their behalf with respect to the matters
discussed herein, and this Agreement and the instruments referenced herein
contain the entire understanding of the parties with respect to the matters
covered herein and therein and, except as specifically set forth herein or
therein, neither the Company nor any Buyer makes any representation,
warranty, covenant or undertaking with respect to such matters.  No
provision of this Agreement may be waived or amended other than by an
instrument in writing signed by the party to be charged with enforcement.

(f) Notices.  Any notices, consents, waivers, or other communications
required or permitted to be given under the terms of this Agreement must be
in writing and will be deemed to have been delivered (i) upon receipt, when
delivered personally; (ii) upon confirmation of receipt, when sent by
facsimile; (iii) three (3) days after being sent by U.S. certified mail, return
receipt requested, or (iv) one (1) day after deposit with a nationally
recognized overnight delivery service, in each case properly addressed to the
party to receive the same.  The addresses and facsimile numbers for such
communications shall be:

If to the Company, to: Access Pharmaceuticals, Inc.
2600 Stemmons Freeway, Suite 176
Dallas, TX 75207
Attention: Kerry P. Gray
Telephone: (214) 905-5100
Facsimile: (214) 905-5101

With a copy to: Bingham McCutchen LLP
150 Federal Street
Boston, MA 02110-1726
Attention: John J. Concannon, Esq.
Telephone: (617) 951-8874
Facsimile: (617) 951-8736

If to the Buyer(s), to its address and facsimile number on Schedule I, with
copies to the Buyer's counsel as set forth on Schedule I.  Each party shall
provide five (5) days' prior written notice to the other party of any change
in address or facsimile number.

(g) Successors and Assigns.  This Agreement shall be binding upon and inure
to the benefit of the parties and their respective successors and assigns.
Neither the Company nor any Buyer shall assign this Agreement or any
rights or obligations hereunder without the prior written consent of the other
party hereto.

(h) No Third Party Beneficiaries.  This Agreement is intended for the benefit
of the parties hereto and their respective permitted successors and assigns,
and is not for the benefit of, nor may any provision hereof be enforced by,
any other person.

(i) Survival.  Unless this Agreement is terminated under Section 9(l), the
representations and warranties of the Company and the Buyer(s) contained
in Sections 2 and 3, the agreements and covenants set forth in Sections 4, 5
and 9, and the indemnification provisions set forth in Section 8, shall survive
the Closing for a period of two (2) years following the date on which the
Convertible Debentures are converted in full or, if earlier, until Convertible
Debentures have been retired.  The Buyer(s) shall be responsible only for its
own representations, warranties, agreements and covenants hereunder.

(j) Publicity.  The Company and the Buyer(s) shall have the right to approve,
before issuance any press release or any other public statement with respect
to the transactions contemplated hereby made by any party; provided,
however, that the Company shall be entitled, without the prior approval of
the Buyer(s), to issue any press release or other public disclosure with
respect to such transactions required under applicable securities or other laws
or regulations (the Company shall use its best efforts to consult the Buyer(s)
in connection with any such press release or other public disclosure prior to
its release and Buyer(s) shall be provided with a copy thereof upon release
thereof).

(k) Further Assurances.  Each party shall do and perform, or cause to be
done and performed, all such further acts and things, and shall execute and
deliver all such other agreements, certificates, instruments and documents,
as the other party may reasonably request in order to carry out the intent and
accomplish the purposes of this Agreement and the consummation of the
transactions contemplated hereby.

(l) Termination.  In the event that the Closing shall not have occurred with
respect to the Buyers on or before five (5) business days from the date hereof
due to the Company's or the Buyer's failure to satisfy the conditions set forth
in Sections 6 and 7 above (and the non-breaching party's failure to waive
such unsatisfied condition(s)), the non-breaching party shall have the option
to terminate this Agreement with respect to such breaching party at the close
of business on such date without liability of any party to any other party;
provided, however, that if this Agreement is terminated by the Company
pursuant to this Section 9(l), the Company shall remain obligated to
reimburse the Buyer(s) for the fees and expenses of Yorkville Advisors
Management, LLC described in Section 4(g) above.

(m) No Strict Construction.  The language used in this Agreement will be
deemed to be the language chosen by the parties to express their mutual
intent, and no rules of strict construction will be applied against any party.

[REMAINDER PAGE INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, the Buyers and the Company have caused this
Securities Purchase Agreement to be duly executed as of the date first written
above.

COMPANY: ACCESS PHARMACEUTICALS, INC.

By:/s/ Kerry P. Gray
--------------------
Name: Kerry P. Gray
Title: President and Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00084-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00084-of-00352.parquet"}]]